Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Bayer Advances Drugs From Tobacco

October 6, 2008 | A version of this story appeared in Volume 86, Issue 40

Bayer and Kentucky Bioprocessing will develop a facility at KBP's Owensboro, Ky., site to produce proteins and other biopharmaceuticals in tobacco plants with Bayer's magnICON technology. According to the partners, by next spring KBP will have adapted its existing facility by installing an automated system for high-throughput transfection of tobacco host plants. Bayer is using the technology to develop therapies such as a vaccine for non-Hodgkin's lymphoma. The firm also plans to license it to third parties.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.